DXR - NASDAQ
Daxor Corporation
$11.09
+3.3%Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
At a Glance
Live SnapshotDaxor Corporation Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Cash flow concerns: Despite profitability, the company is burning cash. Review working capital management, CapEx levels, and sustainability of current operations.
Daxor Corporation Cash Flow Statement
DXR • NASDAQ
| Daxor Corporation Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
9.2M | 536.3K | 280.6K | 5.2M | 4.7M | -1.7M | -495.7K | -885.8K | -1.2M | 1.5M | -9.1M | -976.7K | -8.2M | 1.2M | -7.2M | 5M | 5.8M | 30.2M | 21.3M | -1.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 290.8K | 296.6K | 278.9K | 288.7K | 229.9K | 166.4K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 631.7K | 786.6K | 729.3K | 377.6K | 199.4K | 83.8K | 13.5K | 10.3K | 7.5K | 2.2K | 0.0 | 5.8K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-9.8M | -524.7K | -4.6M | -6.7M | -8.5M | -1.1M | 3.2M | -91.4K | -1.5M | 273.3K | 27.4M | 3.2M | 4M | 4.6M | 5.3M | -13M | -9.6M | -35.9M | -25.9M | -2M | |
21.2K | 14.1K | 52.6K | -9K | 216.8K | -30.7K | 165.7K | -338.5K | 1.5M | -136.4K | 275.2K | -2.6M | -4.8M | -1.3M | -4.9M | 2M | -1.8M | 1.3M | 1.2M | 1.9K | |
-604.4K | 25.7K | -3.7M | -769.3K | -2.8M | -2.4M | 3.1M | -1.3M | -1.2M | 1.6M | 18.5M | -295.6K | -9M | 4.5M | -6.5M | -5.7M | -5.3M | -4M | -3.1M | -3.4M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -123.2K | -324.7K | -2.2M | -666.3K | -1.6M | -344.5K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (65K) | (55K) | (260K) | (195.5K) | (65K) | |
(0.0) | (0.0) | (0.0) | -672.5K | -49.4K | -17.8M | -2.3M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -34.7M | -29.3M | -48.4M | -92.6M | -31.3M | -13.7M | |
1.2M | 1.9M | 2.7M | 3.4M | 124.1K | 18.2M | 7.5M | 0.0 | 0.0 | 0.0 | 2.4M | 0.0 | 0.0 | 0.0 | 9.2M | 20.4M | 50M | 55.1M | 25.2M | 14.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.2M | 18.6M | 26M | 33.9M | 22.3M | 9.8M | |
(1.2M) | (1.9M) | (2.7M) | (2.7M) | (74.8K) | (367.9K) | (5.2M) | (0.0) | (0.0) | (0.0) | (2.4M) | (0.0) | (0.0) | (0.0) | -11.4M | (9.4M) | (25.5M) | -3.9M | (14.8M) | (10M) | |
FINANCING ACTIVITIES | ||||||||||||||||||||
159.3K | 0.0 | 4.5M | 1.9M | 0.0 | 4M | 0.0 | 106.3K | -248.2K | -435.3K | -860.3K | -695.9K | -320.1K | -572.8K | -230.3K | -242.9K | -490.6K | -2.4M | -2.2M | -241.4K | |
-730.2K | -25.7K | -473.5K | -1.8M | 2.9M | -1.2M | -3.1M | 120.1K | 1.5M | -1M | -17.5M | 1.1M | 9.6M | -3.1M | 19.2M | 541.3K | -16.3M | 17.4M | -10.2M | -3.6M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -112.1K | -114K | -154.1K | -119.8K | -204.5K | -833.4K | -1.1M | -4.2M | -5.7M | -6.5M | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -32.2K | -248.2K | -435.3K | -860.3K | -695.9K | -320.1K | -572.8K | -230.3K | -242.9K | -490.6K | -2.4M | -2.5M | -241.4K | |
0.0 | 0.0 | -401.3K | 0.0 | 0.0 | 201.2K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-570.9K | -25.7K | 3.7M | 58.6K | 2.9M | 3.1M | -3.1M | 226.4K | 1.2M | -1.6M | -18.5M | 295.6K | 9M | -4.5M | 17.9M | -3.9M | -22.6M | 8.5M | -12.4M | -3.8M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | -2.7M | -74.8K | -367.9K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -710.7K | 92.9K | 617.8K | 5.2M | -1.1M | -1.1M | 0.0 | 2.4M | 0.0 | 0.0 | 0.0 | 1.9K | -219.3K | -2.3M | 515.2K | -809.1K | 2.7M | |
0.0 | 0.0 | 0.0 | 710.7K | 617.8K | 5.2M | 0.0 | 1.1M | 2.2M | 0.0 | 7.3K | 0.0 | 0.0 | 0.0 | 57.7K | 277.1K | 2.5M | 2M | 2.8M | 93K | |
0.0 | 0.0 | 0.0 | 0.0 | 710.7K | 617.8K | 5.2M | 0.0 | 1.1M | 0.0 | 2.5M | 0.0 | 0.0 | 0.0 | 59.6K | 57.7K | 277.1K | 2.5M | 2M | 2.8M | |
-604.4K | 25.7K | -3.7M | -769.3K | -2.8M | -2.4M | 3.1M | -1.3M | -1.2M | 1.6M | 18.5M | -295.6K | -9M | 4.5M | -6.6M | -6M | -7.4M | -4.7M | -4.8M | -3.8M |
SEC Filings
DXR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 26, 2026 | January 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 23, 2026 | January 23, 2026 | 2026 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 01, 2025 | June 24, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | June 06, 2025 | June 06, 2025 | 2025 | |
8-K 8-K 2024 N/A | July 18, 2024 | July 15, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | June 21, 2024 | June 21, 2024 | 2024 | |
8-K 8-K 2024 N/A | June 05, 2024 | May 30, 2024 | 2024 | |
8-K 8-K 2024 N/A | March 25, 2024 | March 25, 2024 | 2024 |
Related Guides
Continue your DXR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.